bluebird bio, Inc. (NASDAQ:BLUE) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET

Company Participants

Courtney O'Leary - IR

Andrew Obenshain - CEO

Tom Klima - Chief Commercial and Operating Officer

Chris Krawtschuk - CFO

Rich Colvin - Chief Medical Officer

Conference Call Participants

Dane Leone - Raymond James

Jason Gerberry - Bank of America

Eric Joseph - JPMorgan

Gena Wang - Barclays

Jack Allen - Baird

Luca Issi - RBC Capital

Yanan Zhu - Wells Fargo

Brooke Schuster - William Blair

Operator

Good day, and thank you for standing by. Welcome to the bluebird bio Second Quarter Results and Commercial Launch Progress Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Ms. Courtney O'Leary, Investor Relations. Please go ahead.

Courtney O'Leary

Good morning, everyone and thank you for joining today's call. I'm Courtney O'Leary, Investor Relations at bluebird bio.

Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including expectations regarding our future financial results and financial position in addition to statements about the company's plans, expectations or intentions regarding our business, regulatory progress and commercialization plan. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results.

A description of these risks is contained in our most recent Form 10-Q and our other filings with the SEC which are available on the Investor Relations section of our website, www.bluebirdbio.com.

With me on the call is Andrew Obenshain, our CEO, who is going to provide some opening remarks on bluebird's strategic position and vision, and then review our Q2 results. Then, Tom Klima, Chief Commercial and Operating Officer will dive deeper into the positive momentum in our commercial launches and highlight the lovo-cel market opportunity ahead of us. They will then be joined by Chris Krawtschuk, Chief Financial Officer; and Rich Colvin, Chief Medical Officer for Q&A.

With that, I will turn the call over to Andrew.

Andrew Obenshain

Thanks, Courtney, and good morning, everyone.

I want to ground our call this morning on why we're here. A few weeks ago, we heard from a young adult with sickle cell disease who was treated in our HGB-206 study. This was a real privilege. Reflecting on life since gene therapy she shared, it's amazing. My mind is open to the world of possibilities so much in front of me that I want to accomplish. There's so much more for me than one of my previous medical teams had envisioned for me themselves, and I'm excited about it. And this is why we're here. And what we mean when we talk about bringing patients and families more bluebird days.